Bibliography
- EGLEN RM, WATSON N: Selective muscarinic agonists and antagonists. Pharmacol. Toxicol. (1996) 78:59–68.
- EGLEN RM, HEGDE SS: Muscarinic receptor subtypes: pharmacology and therapeutic potential. Drug News Perspect. (1997) 10:462–469.
- CAULFIELD MP: Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther. (1993) 58:319–376.
- ••A comprehensive review of the whole area of muscarinic receptors.
- FISHER A: Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. Exp. Opin. Invest. Drugs (1997) 6:1395–1411.
- NITSCH RN, SLACK BE, WURTMANN RJ, et al. Release of I3-amyloid derivatives by activation of muscarinic acetylcholine receptors. Science (1992) 258:304–307.
- BUXBAUM JD, OISHI M, CHEN HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzhheimer I3/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA (1992) 89:10075–10078.
- RESNICK NM, OUSLANDER JG: National Institute of Health Consensus development conference on urinary incontinence. J. Am. Geriat. Soc. (1990) 38:263–286.
- CUKIER JM, CORTINA-BORJA M, BRADING AF: A case-control study to examine any association between idiopathic detrusor instability and gastrointestinal tract disorder, and between irritable syndrome and urinary tract disorder. Br. J. Urol. (1997) 79:865–878.
- MANFREDA J, MAO Y, LITVEN W: Morbidity and mortality from chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. (1992) 140 (Suppl.) :S19–S26.
- RESNICK NM: Urinary incontinence. Lancet (1995) 346:94–99.
- SWAMI SK, ABRAMS P: Urge incontinence. Urol. Clin. North Am. (1996) 23:417–425.
- YARKER YE, GOA KL, FITTON A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging (1995) 6:243–262.
- CHAPMAN KR: Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus. Am. J. Med. (1996) 100 (Suppl. 1A) :1A-5S.
- DROSSMAN DA, THOMPSON WG: The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann. Intern. Med. (1992) 116:1009–1016.
- EGLEN RM, REDDY H, WATSON N, CHALLISS RAJ: Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol. Sci. (1994) 15:114–119.
- EGLEN RM, HEGDE SS, WATSON N: Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. (1996) 48:531–565.
- ••A large review on the specific area of muscarinic receptors and smooth muscle.
- NILVEBRANT L, HALLEN B, LARSSON G: Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. (1997) 60:1129–1136.
- ALABASTER VA: Discovery and development of selective M2 antagonists for clinical use. Life Sci. (1997) 60:1053–1060.
- HOMMA Y, ASOI Y, KAWABE K, et al. AND STUDY GROUP: Randomized double-blind study to compare clinical efficacy of temiverine and propiverine for unstable bladder and detrusor hyperreflexia. Neurourol. Urodyn. (1997) 16:345–346.
- OSAYU H, YAMAMOTO T, SATO N, et al. Urinary bladder selective action of the new antimuscarinic compound vamicamide. Arzneim.-Forsch./Drug. Res. (1994) 44:1242–1249.
- NAITO R, TAKEUCHI M, MOSIHIRA K, et al. N-biphenylcarbamate derivatives: a novel class of selective muscarinic antagonists. Proceedings of the 14th International Symposium of Medicinal Chemistry (1996). Abstract 2.28.
- MAESEN FPV, SMEETS JJ, SLEDSENS TJH, WALD FDM, CORNEL-ISSEN PJG: Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (1995) 8:1506–1513.
- STEWART WF, KAWAS C, CORRADA M, METTER EJ: Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 48:626–632.
- POIRIER J, DELISLE MC, QUIRION R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. USA (1995) 92:12260–12264.
- ••An important paper relating drug efficacy to different allelic forms of ApoE4.